Inventor · disambiguated record
Thomas Gero
Also filed as: GERO THOMAS · GERO THOMAS W · GERO THOMAS WOODROW
13 granted patents·11 pending applications·83 citations·filing 1990–2025
88Inventor score
Files withASTRAZENECA AB7DANA FARBER CANCER INST INC6NBD NANOTECHNOLOGIES INC4ROBINS CO INC A H3DIEBOLD ROBERT BRUCE1
Top patents by PatentIndex Score
24 records- 0195US9248140B2Chemical compoundsASTRAZENECA AB·Filed 2015·Granted Feb 2, 2016·31 cites·6 claims
- 0293US9018381B2Chemical compoundsDIEBOLD ROBERT BRUCE·Filed 2011·Granted Apr 28, 2015·39 cites·8 claims
- 0392US10442823B2Functionalized F-POSS monomer compositions and uses thereofNBD NANOTECHNOLOGIES INC·Filed 2017·Granted Oct 15, 2019·4 cites·20 claims
- 0487US10174059B2Functionalized F-POSS monomer compositions and uses thereofNBD NANOTECHNOLOGIES INC·Filed 2016·Granted Jan 8, 2019·4 cites·20 claims
- 0580US2023357288A1Functionalized f-poss monomer compositions and uses thereofHENKEL AG & CO KGAA·Filed 2023·Application pending·0 cites
- 0675US2025340534A1Allosteric egfr inhibitors and methods of use thereofDANA FARBER CANCER INST INC·Filed 2025·Application pending·0 cites
- 0775US2025340535A1Allosteric egfr inhibitors and methods of use thereofDANA FARBER CANCER INST INC·Filed 2025·Application pending·0 cites
- 0872US12391671B2Allosteric EGFR inhibitors and methods of use thereofDANA FARBER CANCER INST INC·Filed 2022·Granted Aug 19, 2025·0 cites·29 claims
- 0969US11702433B2Functionalized F-POSS monomer compositions and uses thereofNBD NANOTECHNOLOGIES INC·Filed 2019·Granted Jul 18, 2023·0 cites·15 claims
- 1064US2025388573A1Fused bicyclic egfr inhibitors and methods of use thereofDANA FARBER CANCER INST INC·Filed 2023·Application pending·0 cites
- 1161US7423061B2Substitute thiophenes and uses thereofASTRAZENECA AB·Filed 2004·Granted Sep 9, 2008·1 cites·17 claims
- 1261US2009054396A1Substituted thiophenes and uses thereofASTRAZENECA AB·Filed 2008·Application pending·0 cites
- 1355US2016176906A1Chemical CompoundsASTRAZENECA AB·Filed 2015·Application pending·0 cites
- 1449US12377080B2Allosteric EGFR inhibitors and methods of use thereofDANA FARBER CANCER INST INC·Filed 2020·Granted Aug 5, 2025·0 cites·20 claims
- 1549US2009270450A1Chemical compoundsASTRAZENECA AB·Filed 2009·Application pending·0 cites
- 1648US5109013A2-(2-substituted aminoethyl)-1,4-dialkyl-3,4-dihydro-1H-1,3,5]triazepino[3,2-a]benzimidazol-5(2H)-ones as muscle relaxantsROBINS CO INC A H·Filed 1990·Granted Apr 28, 1992·3 cites·15 claims
- 1748US2009054411A14-anilinoquinoline-3-carboxamides as csf-1r kinase inhibitorsASTRAZENECA AB·Filed 2008·Application pending·0 cites
- 1848US2007010556A1Thiophene derivatives as chk 1 inhibitorsASTRAZENECA AB·Filed 2004·Application pending·0 cites
- 1946US2022233545A1Allosteric egfr inhibitors and methods of use thereofDANA FARBER CANCER INST INC·Filed 2020·Application pending·0 cites
- 2045US2023212171A1Allosteric egfr inhibitors and methods of use thereofSCOTT DAVID A·Filed 2021·Application pending·0 cites
- 2143US9394299B2Rilyazine derivatives and compositions for the treatment of cancerWARNER BABCOCK INST FOR GREEN CHEMISTRY LLC·Filed 2014·Granted Jul 19, 2016·0 cites·9 claims
- 2237US9630981B2Processes for preparing functionalized F-POSS monomersNBD NANOTECHNOLOGIES INC·Filed 2016·Granted Apr 25, 2017·0 cites·20 claims
- 2330US5106857AN-(1-methyl-3-pyrrolidinyl)-1-(phenylmethyl)-1H-benzimidazol-2-amine and analogs as antiarrhythmic and muscle relaxing agentsROBINS CO INC A H·Filed 1991·Granted Apr 21, 1992·1 cites·10 claims
- 2430US5063228A4-(substitutedaminoethyl)-3,4-dihydro-2-alkylpyrimido[1,6-a]benzimidazol-1(2H)-ones as antiarrhythmic agentsROBINS CO INC A H·Filed 1990·Granted Nov 5, 1991·0 cites·15 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →